financetom
Business
financetom
/
Business
/
Nirav Modi claims he has no funds to pay UK court fines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nirav Modi claims he has no funds to pay UK court fines
Mar 10, 2023 12:21 PM

Nirav Modi, the fugitive diamond merchant wanted in India to stand trial on fraud and money laundering charges, has claimed that he has no funds and is resorting to borrowing money to pay the court-ordered legal costs amounting to more than 150,000 pounds.

Share Market Live

NSE

The 52-year-old former billionaire last year lost his legal battle in the highest UK court against being extradited to India in the estimated USD 2 billion Punjab National Bank (PNB) loan scam case. But his case is now said to be “statute barred”, indicating further pending litigation.

Meanwhile, Nirav remains behind bars at Wandsworth Prison in south-west London, from where he appeared via videolink for a hearing at Barkingside Magistrates’ Court in east London on Thursday over unpaid legal costs, or fines, of 150,247 pounds ordered by the High Court in London, related to his extradition appeal proceedings.

Also read: Former diamantaire Nirav Modi’s gems go on sale to pay off $1.5 billion

According to officials, the magistrates at a procedural hearing for court fines granted his plea to be allowed to pay 10,000 pounds a month before a review hearing to take place in six months’ time.

On being asked how he intended to finance the monthly amount, Nirav told the court he had been borrowing money as he did not have sufficient funds because his assets had been frozen in India over the extradition proceedings.

In December last year, a two-judge bench in the Royal Courts of Justice in London refused Nirav Modi’s application for permission to appeal to the Supreme Court on suicide risk grounds and also refused his application to certify a point of law, which concluded his extradition appeal options in the UK courts.

This case may be subject to further litigation, UK Home Office sources have said, which is likely to indicate a parallel confidential political asylum appeals process.

In a final extradition appeal hearing in the case in the London High Court in November 2022, Justices Jeremy Stuart-Smith and Justice Robert Jay ruled that they were “far from satisfied that Mr Modi’s mental condition and the risk of suicide are such that it would be either unjust or oppressive to extradite him”.

Their verdict also accepted that the government of India will treat its assurances on Nirav’s medical care after being extradited and held at Barrack 12 of Arthur Road Jail in Mumbai with “appropriate seriousness”.

The dismissal of the appeal came three years after Nirav Modi was arrested in March 2019 on an extradition warrant based on Central Bureau of Investigation (CBI) and Enforcement Directorate (ED) charges against the businessman.

There are three sets of criminal proceedings against the diamantaire in India – the CBI case of fraud on the PNB which caused losses equivalent to over 700 million pounds, the ED case relating to the alleged laundering of the proceeds of that fraud and a third set of criminal proceedings involving alleged interference with evidence and witnesses in the CBI proceedings.

Then UK Home Secretary, Priti Patel, had ordered Nirav’s extradition based on Judge Sam Goozee’s Westminster Magistrates’ Court ruling in April 2021.

Also read: SC sends to Bombay HC plea against nod granted to Nirav Modi’s brother-in-law to travel to Hong Kong

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
May 24, 2024
May 24 (Reuters) - Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed results from a late-stage trial presented on Friday. The company in March reported that the diabetes drug known chemically as semaglutide cut the combined risk of...
Fairfax Asia Chairman/CEO Athappan Passes Away
Fairfax Asia Chairman/CEO Athappan Passes Away
May 24, 2024
06:31 AM EDT, 05/24/2024 (MT Newswires) -- Fairfax Financial ( FRFHF ) overnight Thursday said Fairfax Asia Chairman and CEO Ramaswamy Athappan has passed away. The company didn't mention the cause of death or Athappan's age. He played a major role in developing Fairfax's insurance operations in Southeast Asia, the company said. Mr. Athappan was an exceptional leader with an...
Workday Cuts Fiscal 2025 Subscription Revenue Guidance Despite First-Quarter Beat
Workday Cuts Fiscal 2025 Subscription Revenue Guidance Despite First-Quarter Beat
May 24, 2024
06:30 AM EDT, 05/24/2024 (MT Newswires) -- Workday (WDAY) shares tanked early Friday as the cloud human resources company lowered its full-year subscription sales outlook amid slowing headcount growth, despite recording better-than-expected fiscal first-quarter results. Subscription revenue is now set to come in between $7.7 billion and $7.73 billion for fiscal 2025, representing annual gains of about 17%, the company...
Update: Workday Fiscal Q1 Earnings, Revenue Rise; FY 2025 Subscription-Revenue Guidance Cut; Shares Sink Premarket
Update: Workday Fiscal Q1 Earnings, Revenue Rise; FY 2025 Subscription-Revenue Guidance Cut; Shares Sink Premarket
May 24, 2024
06:20 AM EDT, 05/24/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Workday (WDAY) shares were down 12% in premarket activity on Friday after the company cut its fiscal 2025 subscription-revenue guidance, taking the shine out of its Q1 earnings and revenue beat. The company reported fiscal Q1 non-GAAP net income late Thursday...
Copyright 2023-2026 - www.financetom.com All Rights Reserved